Ovid Therapeutics Inc. (OVID)
Stock Price:
$7.19 USD
-0.12 (-1.64%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
393.68M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-66.69M |
| Shares Out |
54.75M |
| EPS (ttm) |
-1.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$7.19 |
| Previous Close |
$7.31 |
| Change ($) |
-0.12 |
| Change (%) |
-1.64% |
| Day's Open |
7.55 |
| Day's Range |
7.04 - 7.57 |
| Day's Volume |
1,281,948 |
| 52-Week Range |
1.74 - 9.40 |
More Stats
| Market Cap |
393.68M |
| Enterprise Value |
335.35M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
54.75M |
| Float |
32.80M |
| EPS (basic) |
-1.47 |
| EPS (diluted) |
-1.47 |
| FCF / Share |
-1.04 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.34M |
| Short Ratio |
0.98 |
| Short % of Float |
3.13% |
| Beta |
2.19 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
7.88 |
| Revenue |
n/a |
| Operating Income |
-67.65M |
| Net Income |
-66.69M |
| Free Cash Flow |
-56.70M |
| Net Cash |
58.33M |
| Net Cash / Share |
1.07 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-65.87% |
| ROE |
-122.72% |
| ROIC |
-611.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.43*
(72.88% upside)
Low
8.00
Current: 7.19
High
20.00
Target: 12.43
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -61.41 | -52.93 | -65.01 | -22.54 | -13.19 |
| Net Income | -60.46 | -51.98 | -64.81 | -22.41 | -13.16 |
| Shares Outstanding | 39.22 | 24.63 | 19.34 | 9.84 | 9.70 |
| Earnings Per Share | -1.54 | -2.11 | -3.35 | -2.28 | -1.36 |
| Operating Cash Flow | -51.09 | -45.56 | -31.47 | -17.80 | -5.49 |
| Capital Expenditures | -0.06 | -0.03 | -0.04 | -0.03 | -0.03 |
| Free Cash Flow | -51.15 | -45.59 | -31.51 | -17.83 | -5.52 |
| Cash & Equivalents | 76.74 | 41.50 | 87.13 | 51.94 | 69.94 |
| Net Cash / Debt | 76.74 | 41.50 | 87.13 | 51.94 | 69.94 |
| Assets | 80.84 | 47.65 | 89.46 | 53.03 | 70.38 |
| Liabilities | 10.82 | 8.84 | 6.02 | 3.73 | 2.31 |
| Book Value | 70.02 | 38.81 | 83.44 | 49.29 | 68.07 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Ovid Therapeutics Inc. |
| Country |
United States |
| Employees |
65 |
| CEO |
Jeremy Max Levin |
Stock Information
| Ticker Symbol |
OVID |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: OVID |
| IPO Date |
May 5, 2017 |
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; and strategic research collaboration with Columbia University Irving Medical Center. The company was founded in 2014 and is headquartered in New York, New York.